Farhad Gholami
1, Ali Ghasemi
2, Ahmad Reza Bahrami
3, Hamid Reza Bidkhouri
3, Hojat Naderi Mishkin
4, Masoud Pezeshki Rad
5, Farzaneh Sharifipour
6*1 Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran
2 Department of Hematology and Pediatrics, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Biology, Faculty of Sciences, Ferdowsi University Of Mashhad, Mashhad, Iran 4
4 Academic Center for Education, Culture and Research (ACECR), Stem Cell and Regenerative Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Associate Professor of Radiology, Mashhad University of Medical Sciences, Mashhad, Iran 6
6 Division of Nephrology and Hypertension, Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract
Progenitor cells or mesenchymal stem cells are new cells, with renovation and regeneration
ability and tissues repair. In recent years, administration of stem cells has been introduced to
treat a variety of diseases including chronic allograft injury (CAI). It seems that stem cells can
create a turning point in regenerative medicine through repair, replacement with damaged
tissues or with their paracrine effects.
Implication for health policy/practice/research/medical education:
Mesenchymal non-hematopoietic stem cells are undifferentiated progenitor bone marrow with the ability of renewal and
reconstruction and healing of injured tissues.
Please cite this paper as: Gholami F, Ghasemi A, Bahrami AR, Bidkhouri HR, Naderi Mishkin H, Pezeshki Rad M, et al. The
therapeutic effect of autologous bone marrow mesenchymal stem cells to prevent the progress of chronic allograft nephropathy.
J Renal Inj Prev. 2019;8(1):1-5. DOI: 10.15171/jrip.2019.01.